2026 · 2nd Quarter (Apr 1 - June 30)

FERRING PHARMACEUTICALS INC.

Filed by BROWNSTEIN HYATT FARBER SCHRECK, LLP.

Open official filing

Source-reported fields

Filing overview

Type: 2nd Quarter - Report
Posted: Jul 20, 2026
Income: $50,000.00
Expenses: Not reported
Registrant: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Client: FERRING PHARMACEUTICALS INC.
Filing UUID: 2edde664-cf34-4bd4-bcc6-b79f747a87bb
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

TRD · Trade (domestic/foreign)

Issues related to pharmaceutical tariffs

HCR · Health Issues

Issues related to microbiome, oncology, & fertility Issues related to formulary tier status Drug pricing policy Healthcare policy in the NDAA IVF Tax credit FDA Review programs

VET · Veterans

Issues related to veteran's care and veteran's reproductive care

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.